Background: Recent advances in the development of diagnostic criteria and effective
| INTRODUCTION
Functional gastrointestinal disorders (FGIDs) such as irritable bowel syndrome (IBS) and functional dyspepsia (FD) represent a growing burden to healthcare systems around the world. 1, 2 In the past, therapeutic nihilism and frustration expressed by both patients with
FGIDs and doctors were prevalent. 3, 4 The recent advent of reliable, accepted diagnostic criteria 5, 6 and effective evidence-based management options has potential to transform the FGID landscape. [7] [8] [9] However, clinical practice has not widely adopted these advances:
Consensus-based diagnostic criteria are not widely used, 5, 6, 10 and many primary care providers lack confidence in diagnosing and managing FGIDs and refer to specialty care. [11] [12] [13] The use of unclear diagnostic language and overinvestigation in both primary and specialist care are common, as is continued healthcare utilization in pursuit of a more "acceptable" diagnosis. [14] [15] [16] Although newer, effective management options such as the low-FODMAP diet, gut-directed hypnotherapy, and cognitive behavioral therapy are available, they are not generally used. [7] [8] [9] .
Few models of care for FGID have been evaluated, and the need for the development and validation of a simple clinical pathway for the diagnosis and management of FGIDs is evident. 17 Consensus among gastroenterologists is that, in the absence of alarm features and with negative fecal and blood tests, other tests are rarely warranted to diagnose FGIDs, 18, 19 and an early, clear diagnosis may mitigate much of the frustration, healthcare utilization, and overinvestigation. 14 Thus, to be most effective, a clinical pathway for FGID should incorporate a diagnostic algorithm to successfully move patients from a diagnostic search to an effective management strategy.
To integrate new knowledge into practice and to facilitate the provision of effective health care to this large patient group, we designed and piloted a non-specialist-dependent, algorithm-based approach for the diagnosis and management of FGIDs (ADAM-FGID). 20 Our objectives were to evaluate the safety, feasibility, and acceptability of the ADAM-FGID.
| METHODS

| Recruitment and randomization
All patients (18- 
| Procedure
Patients were invited by a group-specific letter, and provided demographics and baseline measures at intake. The algorithm group underwent a structured screening process for organic disease with a medical history/red flag questionnaire and blood/stool tests (Table   S1 ). Abnormal results were reviewed by a gastroenterologist and, if appropriate, prompt specialist review offered. Participants without alarms were classified using Rome III criteria, and a letter outlining their FGID diagnosis and evidence-based management strategies and resources was sent to patients and primary healthcare providers (PHCPs). A low-FODMAP food list 21 and self-help psychological resource adapted from a previously evaluated booklet 22 were included. Participants were surveyed and outcomes measured 6 weeks, 6 months, and 1 year after intake/diagnosis. The referring PHCPs of the algorithm participants were surveyed at intake and completion to assess the acceptability of the approach to them
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Key Points
• The referral burden for functional gastrointestinal disorders exceeds resource capacity within many public health institutions, resulting in poor patient outcomes.
• The transfer of recent advances in the development of diagnostic criteria and effective management options for functional gastrointestinal disorders into a simple clinical pathway which can be used in primary care may lead to improved patient care and healthcare resource prioritization and reduce patient/provider costs.
• We designed and trialed an algorithm-based approach for the diagnosis and management of FGIDs. The algorithmbased approach was feasible and acceptable to the majority of patients and referring primary healthcare providers. The screening component enabled the earlier detection and management of organic disease.
and the rate of alternative diagnoses in the FGID-diagnosed group at follow-up. Patients who received gastroenterologist review also provided feedback, and non-respondents were contacted to ascertain reasons.
| Measures
Patient satisfaction with symptoms was the primary outcome, measured on a 10-point scale: 1 = not at all satisfied to 10 = completely satis- Participants also identified resources used to access management options. 
| Ethical considerations
| Data analysis
Data were analyzed using SPSS 24 and R version 3.3.3. Descriptive statistics of baseline demographics, Rome III diagnoses, and acceptability to patients and PHCPs are provided as means (standard deviations), medians (interquartile range), frequencies, and percentages, as appropriate. Groups were compared using the chi-square test and Student t test. Qualitative analysis of patient and PHCP feedback is also provided descriptively. Reasons for missing data were obtained. The effect of the intervention was assessed using mixed-effects logistic regressions.
Two models were constructed per outcome assessing the mean difference postbaseline and the difference in change-over-time between intervention and control groups. Age, gender, waitlist duration, and symptom duration were adjusted for as fixed effects, and random intercepts were included per individual. In the mean-difference models, baseline response was included as a fixed effect, while in the changeover-time baseline response was included as an outcome. No attempt was made to account for biases due to differences in consent and attrition. Due to the large number of secondary outcomes, significance was set at 0.01.
| RESULTS
| Sample description
Of the 583 non-urgent referrals, 445 were deemed "likely FGID," and 307 of these fulfilled inclusion criteria (66% female). Of 211 patients al- of the control group had seen a gastroenterologist previously (vs 30%
algorithm, P = .036) ( Table 1 ).
| Safety of the algorithm-based screening
Of the 89 algorithm patients screened, 35 (39%) had alarms elicited by structured screening and had prompt gastroenterologist (GE) review; in the other 54 (61%), there were no alarms and most (n = 45)
were diagnosed with a FGID ( 
| Feasibility of the approach
Six-week qualitative feedback was obtained from 36/45 patients diagnosed with FGID by the algorithm (34 completed full questionnaire, and 2 completed short phone survey). Responders and non-responders were comparable in age, gender, employment/relationship status, and primary language (all P > .05). Tertiary-educated participants responded more commonly than those without this level of education (86% vs 64%, P = .032). Non-response reasons included disagreement with the diagnosis/desire to see a specialist (n = 2), lack of time (n = 1), psychiatric inpatient (n = 1), symptom resolution (n = 1), and lost contact (n = 4).
All but one had read the letter, and the majority of respondents (25/36) found it useful (17 useful, 8 partially useful; Table S2 ).
T A B L E 1 Demographic comparison of patients allocated to the algorithm or waitlist control group, and screened patients diagnosed with FGID or requiring GE consult ported it to be a realistic, manageable, and affordable option (Table   S3) . Time, cost, and lack of perceived relevance or acceptance of psychological therapies were the main reasons cited for lack of its uptake.
Do-it-yourself options were preferred (Figure 2 ). Even when using psychological management options, some respondents (n = 5) did not identify them as such.
While the pilot was not powered for efficacy, symptomatic im- 
| Acceptability of the approach
The approach was at least moderately acceptable to 68% (54/80) of patients ( Figure 1 ). Of those providing free-text responses (n = 31), the screening process was rated as relevant/efficient (n = 7) and better than a long waiting list (n = 5). It reassured the FGID diagnosis group (n = 4), provided helpful options for managing their symptoms (n = 5), and expedited gastroenterologist review for those with alarms (n = 10). Three in the screen-fail group felt cared for with their concerns addressed (n = 3), and 2 liked the ease of the whole approach. Those who found the approach unacceptable or only slightly acceptable expressed dissatisfaction with the healthcare system (n = 4) or the FGID diagnosis (n = 3), irrelevance of screening questionnaire (n = 1), and lack of improvement in symptoms (n = 1) (Table   S5 ). Only 2 participants in the screen-fail group found it "not at all acceptable"; one of these had relocated, missed their endoscopy, and was discharged from the system, and another discovered the symptoms were related to taking the wrong medication.
T A B L E 2 Screening results and final diagnosis of FGID and GE consult groups
Overall, 60/89 referring PHCPs responded to the intake survey leading to litigation n = 2) and patient expectation/satisfaction (n = 3).
At completion, all responding PHCPs found the approach at least mod- 14 FGID group, 9 screen-fail group), with acceptability unrelated to whether their patient saw a specialist or received a diagnostic letter (P = .507). PHCPs opined that this approach was likely to reduce waiting lists and colonoscopies, and provided reassurance for PHCPs and patients (Table S5 ). Fear of missed pathology or litigation was not raised in the follow-up surveys, although duplication of tests already performed and patient insistence on further investigation were mentioned.
| DISCUSSION
This study provides the first data on a non-specialist-dependent path- In the local context of this tertiary referral system, in a country with a well-developed healthcare system, this algorithm-based screening approach proved safer than current practice. It facilitated the earlier detection and management of organic disease. Currently, referrals with no declared alarms, for clinically suspected FGIDs, are triaged as non-urgent and patients are placed on long waiting lists (>2 years, with many not being seen). This pilot study identified that one-third of those triaged as non-urgent warranted more urgent gastroenterology review, and would have received such if this screening had occurred in primary care and was declared on referral. These pilot data are encouraging and justify a further larger scale evaluation, with potentially even greater gains within less developed healthcare systems.
| Strengths of the approach
| Good patient and PHCP buy-in
The results demonstrate the feasibility of a non-specialist-dependent approach conducted via mail/online surveys. Patient buy-in was high, with only 1 participant finding it too difficult to complete screening.
The approach was also well received by PHCPs. Reasons for positive feedback included acknowledgment of the likely outcomes of reduction in both waitlist time and unnecessary investigations, along with the value of the written material as an educational resource and a basis for further discussions, which is likely to lead to further capability building via PHCP education and confidence building. No major concerns with the approach were identified by referring clinicians, other than the potential for duplication of tests already performed within primary care, which could be avoided if the approach were embedded in primary care prior to a referral being made.
| Facilitation of diagnosis
The starting point for this diagnostic pathway was the PHCP referral letter, which was in general poor, as previously reported.
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Information was insufficient to allow safe triage according to urgency as evidenced by the fact that structured screening found that 2 of 5 patients warranted more urgent gastroenterologist review with a subsequent diagnosis of organic disease in nearly a third of these. Using this structured screening approach in tertiary care as a triage mechanism mandates a considerable time commitment by the gastroenterologist, which could be minimized using a nurse specialist.
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| Acceptance of this diagnostic pathway
Most participants found the pathway acceptable, particularly those in whom clinical alarms were identified and a gastroenterologist consult expedited. Almost every patient with clinical red flags also had abnormal test (blood/stool) results, and thus, the opportunity to "game the system" was minimized. Even among those diagnosed with a FGID
and not offered specialist review, 62% found the approach acceptable, acknowledging its convenience and efficiency, and went on to engage with the management options. Patients were reassured by the screening process. 
| Shared care
We had anticipated that the letter would provide a shared resource
PHCPs and patients could use to tailor an individualized management approach. However, less than a third of participants discussed their diagnostic/management letter with their referring doctor. The importance of continued PHCP management should not be underestimated. PHCPs play a vital role in empowering patients to manage their own symptoms, particularly in chronic disease management 33 and medically unexplained symptoms such as FGIDs. 4 Furthermore, PHCPs play a growing role in interpreting knowledge patients gather from various informal sources, such as peers, social media, and websites. 4 Better patient outcomes may have been seen if the letter explicitly stated the importance of arranging an appointment with their GP as the next step in management.
| Self-management
The patients clearly showed considerable interest in self-management, particularly via dietary manipulation. It has been previously shown that diet is the primary behavioral factor manipulated by women with IBS. 34 The low-FODMAP diet is the only dietary approach with a strong evidence base, with 50%-75% 35-37 of patients obtaining considerable symptomatic relief. However, no trials on self-administered low-FODMAP diet have been reported, and self-implementation is not currently recommended. [38] [39] [40] Furthermore, a profusion of written and electronic low-FODMAP resources have been developed and are publicly available, but the accuracy of such resources has been seriously questioned. 41 Given the strong interest in self-management, further efforts to develop a safe and effective dietary self-management approach are warranted. 
| Acceptance of psychological interventions
| Strengths and limitations of the study
There are several potential limitations to the interpretation and generalizability of the results of this study. The study was designed to maximize the potential of having a control comparator group, by randomizing to groups prior to invitation. This approach is considered clinically relevant and acceptable, particularly in a pilot study, as people with FGIDs are difficult to recruit due to the chance of being allocated to the control arm. 45 However, the low control group response rate means that we cannot claim successful randomization. Given the large proportion of non-completers, the study was analyzed as if it was non-randomized (observational), with no attempt being made to account for biases due to dropout. However, we attempted to minimize the effect of attrition by accounting for reasons for dropout.
The small sample size of the control and algorithm groups is also a potential limitation to generalizability, particularly given the final follow-up sample size. There was also a greater percentage of patients who had previously seen a gastroenterologist for their symptoms, and who had psychological symptoms in the control group, and thus, the control group may represent a cohort that is more difficult to treat.
A larger size, randomized control trial with an intent-to-treat analysis and imputation of missing data is needed to investigate this model of care further. setting would be beneficial.
| CONCLUSION
We have demonstrated that this novel, comprehensive clinical pathway for the diagnosis and management of FGIDs, which is not dependent upon specialist review, is feasible, acceptable and may provide greater safety than the current approach by facilitating the earlier detection and management of organic disease. This is important given the size of this patient group and the resultant public health implications. Implementation of this model within primary care would enhance efficiency of care for this large patient group, build capacity, reduce specialist burden (time and cost), and fast-track effective care.
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